Biotest Sustainability Profile
Biotest AG, a leading player in the biopharmaceutical industry, is headquartered in Dreieich, Germany. Founded in 1946, the company has established itself as a pioneer in the development and production of immunoglobulins and blood plasma products. With a strong focus on therapeutic areas such as immunology and haematology, Biotest is committed to enhancing patient care through innovative solutions. The company’s core offerings include high-quality plasma-derived therapies, which are distinguished by their rigorous quality standards and advanced manufacturing processes. Biotest has achieved significant milestones, including the expansion of its global presence, with operations spanning Europe, North America, and Asia. Renowned for its commitment to research and development, Biotest continues to solidify its market position as a trusted provider of essential biopharmaceuticals, contributing to improved health outcomes worldwide.
DitchCarbon Score
How does Biotest's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biotest's score of 42 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biotest's reported carbon emissions
In 2022, Biotest reported total carbon emissions of approximately 18,185,600 kg CO2e from Scope 1 and 930,500 kg CO2e from Scope 2, resulting in a combined total of about 19,116,100 kg CO2e. This marks a significant reduction from previous years, where emissions were approximately 27,807,200 kg CO2e in both 2019 and 2020, and about 20,544,000 kg CO2e in 2021. Biotest's emissions data is cascaded from its parent company, Grifols, S.A., indicating a corporate family relationship that influences its climate commitments. However, there are currently no specific reduction targets or initiatives reported under the Science Based Targets initiative (SBTi) or other climate pledges. The company has disclosed emissions data for Scope 1 and Scope 2 but has not provided information on Scope 3 emissions. Biotest's commitment to sustainability is evident through its transparency in reporting, although further details on specific reduction initiatives or targets would enhance its climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 893,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 16,537,200 | 000,000 | 000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Biotest's Industry?
How Carbon Intensive is Biotest's Location?
Biotest's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biotest has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
